Eosinophilia: Clinical Trials

84 trials for Eosinophilia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

54 completed, 8 terminated, 6 active not recruiting, 6 recruiting. 84 Phase 2, 8 Phase 1, 7 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 284Completed 54, Terminated 8, Active not recruiting 6, Recruiting 6, Unknown 6, Withdrawn 3, Not yet recruiting 1
Phase 18Completed 4, Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1
Phase 37Completed 6, Unknown 1

Follow Eosinophilia: new trials by email Literature Review of Eosinophilia trials Research Report on Eosinophilia

Trials (filtered) newest first · largest first

All 84 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis
Upadacitinib 30mg Dose, Upadacitinib Matching Placebo - EoE, Eosinophilic Esophagitis
Phase 2RecruitingUniversity of North Carolina, Chapel Hill522026-09-302026-10-06
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
KT-621, Placebo - Eosinophilic Asthma
Phase 2RecruitingKymera Therapeutics, Inc.2642026-01-282026-10-06
A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma
AD17002, Formulation buffer - Eosinophilic Asthma
Phase 2Not yet recruitingAdvagene Biopharma Co. Ltd.1262025-12-012025-11-26
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
Vonoprazan, Placebo - Eosinophilic Esophagitis
Phase 2Active not recruitingPhathom Pharmaceuticals, Inc.952025-10-302026-10-13
Zemaira Eosinophilic Esophagitis Pilot Study
Alpha-proteinase inhibitor - Eosinophilic Esophagitis
Phase 2RecruitingChildren's Hospital Medical Center, Cincinnati152025-05-152025-12-17
Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents
dupilumab - Hypereosinophilic Syndrome
Phase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)302025-02-052026-11-06
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
Dupilumab, Fluticasone - Eosinophilic Esophagitis
Phase 2RecruitingUniversity of Colorado, Denver722024-12-232025-03-14
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose - Eosinophilic Esophagitis (EoE)
Phase 2Active not recruitingUniquity One (UNI)1842024-10-162026-03-20
AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
AD17002, Placebo - Eosinophilic Asthma
Phase 1 / Phase 2CompletedAdvagene Biopharma Co. Ltd.402023-11-272025-09-10
A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
barzolvolimab, Matching Placebo - Eosinophilic Esophagitis
Phase 2CompletedCelldex Therapeutics862023-06-012026-05-27
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
Dupilumab - Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD)
Phase 2Active not recruitingRegeneron Pharmaceuticals222023-05-032026-07-01
A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
EP-104GI, Matching vehicle control - Eosinophilic Esophagitis
Phase 1 / Phase 2RecruitingEupraxia Pharmaceuticals Inc.1172023-03-312026-03-19
Mesalazine Oral Suspension in Active Eosinophilic Esophagitis
Mesalamine Oral Product - Eosinophilic Esophagitis
Phase 2CompletedDr. Falk Pharma GmbH52023-02-092023-09-07
A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis
NDX-3315, NDX-3324, SPECT/CT Imaging - Eosinophilic Esophagitis
Phase 2CompletedNexEos Diagnostics, Inc.342023-01-202026-05-14
A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma
610 100mg, 610 300mg, placebo - Asthma
Phase 2UnknownSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.1202022-09-012022-09-06
Targeted Elimination Diet in EoE Patients Following Identification of Trigger Nutrients Using Confocal Laser Endomicroscopy
personalized exclusion diet based on CLE, empiric exclusion diet - Eosinophilic Esophagitis
Phase 1 / Phase 2UnknownUniversitaire Ziekenhuizen KU Leuven252022-02-162024-06-27
A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis
IRL201104, Placebo - Eosinophilic Esophagitis
Phase 2CompletedRevolo Biotherapeutics362021-10-292025-05-21
A Study to Investigate the Efficacy and Tolerability of ESO-101 in Patients With Eosinophilic Esophagitis
ESO-101, Placebo - Eosinophilic Esophagitis
Phase 2CompletedEsoCap AG432021-06-292023-11-14
Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults' Subjects of Both Genders With Eosinophilic Esophagitis (EoE)
Budesonide Gel - Eosinophilic Esophagitis
Phase 2WithdrawnBazell Pharma AG2021-04-232024-08-23
Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic Esophagitis
Florence 30 μg/mL, Florence 60 μg/mL, Florence 90 μg/mL - Eosinophilic Esophagitis
Phase 2UnknownEMS1162021-04-192023-02-24

Showing 20 of 84. Sign in to see all of them.

Narrower conditions

Eosinophilic Esophagitis (50)  ·  Hypereosinophilic Syndrome (16)  ·  Esophagitis (10)  ·  Pulmonary Eosinophilia (10)  ·  Asthma (8)  ·  Deglutition Disorders (4)  ·  Eosinophilic enteropathy (4)  ·  Gastroesophageal Reflux (4)  ·  Myeloproliferative Disorders (4)  ·  Esophageal Diseases (3)  ·  Leukemia (3)  ·  Leukemia, Myelomonocytic, Chronic (3)  ·  Myelodysplastic Syndromes (3)  ·  Polycythemia Vera (3)

Broader conditions

Hemic and Lymphatic Diseases (84)  ·  Hematologic Diseases (83)  ·  Leukocyte Disorders (83)  ·  Immune System Diseases (64)  ·  Hypersensitivity, Immediate (59)  ·  Hypersensitivity (58)  ·  Gastroenteritis (50)  ·  Digestive System Diseases (49)  ·  Gastrointestinal Diseases (49)  ·  Esophageal Diseases (47)  ·  Esophagitis (40)  ·  Respiratory Tract Diseases (18)  ·  Lung Diseases (17)  ·  Pathological Conditions, Signs and Symptoms (13)

Interventions

Imatinib Mesylate (7)  ·  Budesonide (6)  ·  Fluticasone (6)  ·  mepolizumab (5)  ·  dupilumab (4)  ·  (5-fluoro-2-methyl-3-quinolin-2-ylmethylindo-1-yl)acetic acid (3)  ·  AK002 (3)  ·  Dexpramipexole (3)  ·  Sodium Chloride (3)  ·  Esomeprazole (2)  ·  Losartan (2)  ·  Mometasone Furoate (2)  ·  benralizumab (2)  ·  fevipiprant (2)  ·  heat-labile enterotoxin, E coli (2)

Sponsors

Novartis Pharmaceuticals (7)  ·  Children's Hospital Medical Center, Cincinnati (6)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (5)  ·  Mayo Clinic (4)  ·  Allakos Inc. (3)  ·  M.D. Anderson Cancer Center (3)  ·  Advagene Biopharma Co. Ltd. (2)  ·  Dr. Falk Pharma GmbH (2)  ·  Knopp Biosciences (2)  ·  National Institutes of Health Clinical Center (CC) (2)  ·  Regeneron Pharmaceuticals (2)  ·  Shire (2)  ·  Swiss EE Study Group (2)  ·  University of North Carolina, Chapel Hill (2)  ·  University of Utah (2)

Countries

United States (58)  ·  United Kingdom (13)  ·  Switzerland (12)  ·  Canada (10)  ·  Germany (10)  ·  Belgium (9)  ·  Spain (9)  ·  Italy (8)  ·  Australia (7)  ·  Poland (7)  ·  Netherlands (6)  ·  Austria (4)  ·  France (3)  ·  Japan (3)  ·  Taiwan (3)

Top investigators

Amy D Klion, M.D. (4)  ·  Marc E Rothenberg, MD, PhD (3)  ·  Craig Paterson, MD (2)  ·  Evan S Dellon, MD, MPH (2)  ·  John C. Fang, M.D. (2)  ·  Alex Straumann, Dr (1)  ·  Alex Straumann, MD (1)  ·  Amy Foxx-Orenstein, D.O. (1)  ·  Andrew W Lee, MD (1)  ·  Antonella Cianferoni, MD, PhD (1)  ·  Antonio T. Fojo, MD, PhD (1)  ·  Bruce Randazzo, MD (1)

Results publications

PMID 12676775, PMID 14504092, PMID 16775235, PMID 17709602, PMID 17715389, PMID 19451433, PMID 19735261, PMID 20457157, PMID 21098399, PMID 22111863, PMID 22206777, PMID 23547655, PMID 24057647, PMID 24768678, PMID 24907494, PMID 24907502, PMID 25226850, PMID 25792708, PMID 26002753, PMID 26797802, PMID 27889574, PMID 29739754, PMID 29902649, PMID 30395812, PMID 30476587, PMID 30502508, PMID 31100455, PMID 31593702, PMID 31659803, PMID 32205221, PMID 32272243, PMID 33085861, PMID 33595845, PMID 33831327, PMID 34037993, PMID 34089846, PMID 34110505, PMID 35181572, PMID 35248549, PMID 35283330, PMID 35636689, PMID 35666852, PMID 36863390, PMID 37285821, PMID 37422688, PMID 37423717, PMID 37718471, PMID 37753954, PMID 37934000, PMID 37951310

NIH funding

2016 (2), U54AI117804 (2), 2009 (1), 2014 (1), 2015 (1), 2017 (1), 2018 (1), R01DK135692 (1), R01DK146043 (1)